# **OUR PIPELINE**


We are building a pipeline of *in vivo* and *ex vivo* therapies, as well as continuing to develop innovative modular platform capabilities.



LAST UPDATED: FEBRUARY 22, 2024

### **IN VIVO PROGRAMS**

## **IN VIVO** CRISPR **is** the therapy **GENETIC DISEASES**



### **EX VIVO PROGRAMS**

#### **EX VIVO** CRISPR **creates** the therapy IMMUNO-ONCOLOGY / AUTOIMMUNE DISEASE

PROGRAM	APPROACH	RESEARCH AND PRECLINICAL	EARLY-STAGE CLINICAL	LATE-STAGE CLINICAL	PARTNERS
Research Programs	Allogeneic and other				kyverna
TD: Alpha-1 Antitrypsin Deficiency ad refers to lead development and commercial party.			** Hemophilia A p	<ul> <li>* Intellia is advancing both wholly-owned and partnered programs.</li> <li>** Hemophilia A program is in the research stage.</li> <li>*** This program is being advanced by Regeneron. Intellia is eligible for milestones and partnered program is being advanced by Regeneron.</li> </ul>	